Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Picolight + Clicolon is a combination bowel preparation regimen evaluated for its efficacy and tolerability in patients undergoing colonoscopy for colorectal cancer screening. The regimen combines Picolight, a stimulant and osmotic laxative containing sodium picosulfate, magnesium oxide, and citric acid, with Clicolon, an oral sodium phosphate tablet. Sodium picosulfate is a prodrug metabolized by colonic bacteria into an active metabolite that stimulates colonic peristalsis, while magnesium citrate (formed in solution) and sodium phosphate act as osmotic laxatives, drawing water into the intestinal lumen to facilitate bowel cleansing. This combination approach is designed to reduce the total volume of fluid intake required for preparation, thereby improving patient compliance and reducing side effects compared to standard high-volume polyethylene glycol (PEG) solutions. It has been studied in Phase II trials by the National Cancer Center, Korea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Picolight + Clicolon.